Osteomyelitis (bone infection) is a 1.7 billion-dollar (US) market. Standard treatment currently consists of long-term courses of antibiotics, repeated surgical operations (due to constant failure), and possible amputation. The increasing incidence of prosthetic infections, as well as diabetic ulcers, war and sports injuries, and growing antibiotic resistance, are all contributing to a rise in osteomyelitis rates. Bone infections are often very hard to manage and may require two-stage operations. “Our challenge was to develop a new generation of bone substitute that helps maintain bone integrity and growth while also actively treating infections.
NexGenic launches ImageInbox app for patient transfer, control & ownership of medical images & reports
NexGenic, LLC announces its ImageInbox® app is available today as a free Android app in the Google Play Store, allowing patients everywhere to securely share medical images. The new Android OS extends the ImageInbox® image […]
Evonik, a German speciality chemicals company, is conducting research on new biodegradable 3D printing materials which could be used in the fixation of fractured bones. The composite materials could eventually replace the metals traditionally used […]